Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EVs) & Nanoparticles 2024: Diagnostics, Delivery, Therapeutics

Steven Stice's Biography



Steven Stice, Co-Founder and Chief Scientific Officer, Aruna Bio; DW Brook Distinguished Professor and Director of the Regenerative Bioscience Center, Georgia Research Alliance Eminent Scholar, University of Georgia

Dr. Steven Stice is Co-Founder and Chief Scientific Officer of Aruna Bio, where he directs the company’s clinical and research operations. He is also University of Georgia, DW Brooks Distinguished Professor and Director of the Regenerative Bioscience Center, and holds a Georgia Research Alliance Eminent Scholar endowed chair. Prior to joining Aruna, Dr. Stice was the co-founder and served as both Chief Scientific Officer and Chief Executive Officer of Advanced Cell Technology, the first U.S. company to advance to human clinical trials using human pluripotent stem cells. He also co-founded startups Prolinia and Cytogenesis, the latter of which has since merged with ViaCyte.

Dr. Stice was recruited to the University of Georgia by the Georgia Research Alliance (GRA) and holds an endowed chair as a GRA Eminant Scholar. Additionally, Stice serves as the Director of the Univeristy of Georgia’s Regenerative Bioscience Center, co-directs The Regenerative Engineering and Medicine Research Center (REM), a joint collaboration between Emory University, Georgia Institute of Technology and UGA, is a group leader of Emergent Behaviors of Integrated Cellular Systems, a National Science Foundation Center founded by the Massachusetts Institute of Technology. Stice also sits on the toxicology Scientific Advisory Board for the Food and Drug Administration (FDA). Dr. Stice received a Masters of Science in Reproductive Biology from Iowa State University and a Doctor of Philosophy, Developmental Biology and Embryology, from the University of Massachusetts.

Steven Stice Image

Moving Neural Stem Cell Derived Exosome into Clinical Trials: Manufacturing and Mechanistic Considerations

Wednesday, 3 April 2024 at 10:00

Add to Calendar ▼2024-04-03 10:00:002024-04-03 11:00:00Europe/LondonMoving Neural Stem Cell Derived Exosome into Clinical Trials: Manufacturing and Mechanistic ConsiderationsExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami, FloridaSELECTBIOenquiries@selectbiosciences.com

Neural stem cell EVs (NSC EVs) derived in bioreactors have therapeutic potential for treating neurological disease and acute ischemic stroke (AIS). New FDA Investigational New Drug (IND) applications are being filed and specifically, we have an open IND for AIS. As the field grows, new INDs will be filed for various other therapeutic indications. In order for EV therapeutics to move efficiently through the regulatory process to approval, there is a need for more emphasis on and development of analytical assays directly related to complex, and likely multimodal, mechanisms of action. Research focused on this area will lead to new disease-specific potency assays and identification of critical quality attributes. Beyond AIS, one of the most promising applications of NSC EVs is in the treatment of amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative disease that affects the motor neurons in the brain and spinal cord. In a preliminary study, we have shown that NSC EVs significantly preserved motor function, decreased serum neurofilament light chain, and prolonged survival in ALS mice. NSC EVs also reduced inflammatory mediators TNFa, IL-1ß, IL-6, RIPK1, and NLRP3 in the lumbar spinal. These results suggest that NSC EVs have the potential to be developed as a therapeutic for ALS. The complex pathogenesis in the central nervous system during ALS suggests the need to develop drugs with multimodal therapeutic action and will likely require the development of multiple potency assays relevant to the active agents in and on the surface of the NSC EVs.


Add to Calendar ▼2024-04-03 00:00:002024-04-04 00:00:00Europe/LondonExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, TherapeuticsExtracellular Vesicles (EVs) and Nanoparticles 2024: Diagnostics, Delivery, Therapeutics in Miami, FloridaMiami, FloridaSELECTBIOenquiries@selectbiosciences.com